Contact
Please use this form to send email to PR contact of this press release:
Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center
TO:
Please use this form to send email to PR contact of this press release:
Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center
TO: